Cryopreservation of PBSC for allo-SCT offers potential advantages; however, its impact on engraftment and outcomes remains unclear. A total of 76 allo-SCT performed using cryopreserved PBSC from HLA identical related (n ¼ 57) and unrelated donors (n ¼ 19) were compared with 123 fresh PBSC allo-SCT. Median neutrophil engraftment was on day 12 for both cryopreserved and fresh PBSC; in multivariate analysis, there was a slight but significant delay in neutrophil engraftment after the median date (hazard ratio (HR) ¼ 1.44, P ¼ 0.003). Platelet engraftment was significantly delayed in cryopreserved PBSC recipients (median time 19 vs 14 days). In multivariate analysis cryopreservation (HR ¼ 1.85, Po0.001), earlier date of transplant and lower CD34 þ cell dose were associated with delayed platelet engraftment. Two-year OS and relapse and 1-year TRM rates did not differ significantly. Acute GVHD incidence was comparable, and extensive chronic GVHD at 1 year was higher in cryopreserved PBSC recipients (40.3 vs 28.3%), but not significantly so (P ¼ 0.13). Cryopreservation of related and unrelated donor allogeneic PBSC is safe and effective where its benefits outweigh the risks of delayed platelet engraftment; its impact on chronic GVHD incidence requires further assessment.
INTRODUCTION
In allo-SCT, cryopreserved PBSC account for less than 2% of transplants performed. 1 Logistical advantages of cryopreservation include more flexible bed management, the delivery of PBSC internationally without concern regarding transport delays and the ability to delay a transplant to allow treatment of a problem in the recipient (for example, intercurrent infection) without having to alter the PBSC harvest arrangements. Additionally, where there is concern that a related donor might yield a suboptimal PBSC dose due to age or body mass, cryopreservation allows assurance that an adequate cell dose is available before commencing conditioning. Potential pitfalls of cryopreservation are: (i) cryopreservation of cells may impair cell viability and hence engraftment, (ii) cryopreservation may alter lymphoid viability or function thereby altering GVHD incidence or GVL effect and (iii) should the transplant not take place then a healthy donor has been put through an unnecessary procedure. Apart from (iii), the concerns raised generally have not been supported by studies to date.
Several studies report comparable engraftment and survival rates between cryopreserved and fresh BM allo-SCT from HLAidentical related donors (RD). [2] [3] [4] [5] [6] Only one study has examined cryopreserved PBSC allo-SCT in depth; 7 105 patients receiving cryopreserved PBSC allo-SCT were compared with a historical control receiving fresh PBSC. There were no differences in neutrophil or platelet engraftment time, acute or chronic GVHD incidences nor in survival, relapse and TRM-however, it is important to note that no unrelated donors were included in this series.
PBSC vs BM and matched unrelated donors (MUD) vs RD may not be comparable with respect to the cryopreservation outcomes. Lioznov et al. 8 in a study of 46 patients, 35 receiving MUD allografts, found that stem cell viability and CD34 þ cell membrane integrity were significantly impaired in PBSC, but not in BM, after cryopreservation. Worryingly, 9 of 33 cryopreserved PBSC grafts, all from MUD, failed to engraft. Stockschläder et al. 9 reported transplantation of cryopreserved MUD allogeneic BM in 10 patients, demonstrating that engraftment occurred. Follow up, however, was short and only five patients were alive at 100 days post-transplant.
In summary, there may be significant problems with cryopreservation of PBSC, and there are no published data on the longterm outcomes of allo-SCT using cryopreserved PBSC from MUD. In addition, there are limited data on long-term follow-up of reduced intensity-conditioned (RIC) and myeloablative (MAC) allo-SCT using cryopreserved PBSC. Here, we examine medium to long-term outcomes following the use of cryopreserved PBSC in 76 allo-SCT, including 19 from MUD.
PATIENTS AND METHODS

Eligibility and criteria for cryopreservation
Patients who received a first MAC or RIC allo-SCT from an adult donor using cryopreserved PBSC from 2004 onwards were included. Controls comprised first fresh PBSC allo-SCTs performed over a similar time period. All patients gave written consent before transplant for the collection and analysis of anonymous data in subsequent studies of transplant outcomes. Institutional criteria for cryopreservation of related donor PBSC were donor age 460, donor weight 440% less than recipient weight and where the donor had comorbid conditions that the transplant physician felt might compromise stem cell harvest. Cryopreservation or related and unrelated donor PBSC was also used for logistical reasons, as outlined in the results.
Transplant conditioning
Details of the conditioning regimens used are listed in Table 1 . Sibling MAC allo-SCT recipients received MTX 8 mg/m 2 on days 2, 4, 8 and 11 posttransplant as GVHD prophylaxis, whereas recipients of MAC MUD allo-SCT also received alemtuzumab (total dose 50 mg). RIC GVHD prophylaxis comprised alemtuzumab (total dose 50 mg) and MTX 10 mg/m 2 on days 1, 3 and 6. In aplastic anaemia and transplants using the FLAMSA regimen, anti-thymocyte globulin was used instead of alemtuzumab. All patients received CsA from day À 1 with the dose weaned to zero from day 90-120 post-transplant in the absence of GVHD.
Stem cell harvesting, processing and storage PBSC from related donors were mobilised using Filgrastim 10 mcg/kg/day for 5 days with a target PBSC collection of 4 Â 10 6 CD34 þ cells/kg recipient weight, collected by 1-3 days of peripheral blood apheresis. Enumeration of viable CD34 þ and CD3 þ content using single platform lyse-no-wash flow cytometry assays on a BD FACSCanto (BD BioSciences, Oxford, UK) was performed on all apheresis products. PBSC issued fresh were diluted to 200 Â 10 6 /mL with either autologous plasma or 4.5% Human Serum Albumin (Bio Products Laboratory Ltd, Herts, UK) and stored at 4 o C before distribution. For cryopreservation, apheresis products were diluted to 200 Â 10 6 /mL as above and were processed in ISO 7 grade clean rooms or using a closed process (CryoDoc, Origen Biomedical, Austin, TX, USA). DMSO (Origen Biomedical) at a final concentration of 10% was used as a cryoprotectant. Apheresis products were aliquoted into cryocyte bags (Origen Biomedical), frozen in controlled rate freezers (Planer PLC, Middlesex, UK) and transferred to vapour phase LN2 storage ( À 150 o C). Cryopreserved products were distributed to hospital wards using validated dry shippers (Planer PLC), and were thawed at the bedside for infusion without further manipulation. Cell viability was not tested post-thaw; cells were returned immediately on thawing. CD34 þ doses listed represent prefreeze counts.
Definitions
Diagnoses defined as 'myeloid' were (n): AML (101), myelodysplastic syndrome (16), CML (14) , myelofibrosis (6); diagnoses considered 'lymphoid' were (n): non-Hodgkin's lymphoma (34), ALL (17), Hodgkin's lymphoma (10), CLL (5), myeloma (5) and aplastic anaemia (2) . Neutrophil and platelet engraftment were defined as time from day 0 until the first of 3 consecutive days when ANC exceeded 0.5 Â 10 9 /L and platelet count exceeded 50 Â 10 9 /L without platelet transfusion support, respectively. OS was measured from the time of transplantation to death, relapse-free survival (RFS) was measured from the time of transplantation to relapse or death, relapse incidence and TRM were measured from the time of Cryopreservation of allogeneic PBSC P Medd et al transplantation to the time of relapse or death in remission, respectively. Acute and chronic GVHD incidences were measured from the time of transplantation to the date of diagnosis of grades 2-4 acute or extensive chronic GVHD, respectively.
Statistical analysis
The fresh and cryopreserved PBSC groups were compared using Fisher's exact test, the w 2 test for trend and the Mann-Whitney U test. OS and RFS were calculated using the Kaplan-Meier estimate. Cumulative incidence in a competing risks setting was used to calculate the following (competing risk for each event in brackets): engraftment (death without engraftment or stem cell 'top-up' or second transplant), relapse incidence (death in remission), TRM (relapse), grades 2-4 acute GVHD (death before day 100 without grades 2-4 acute GVHD) and chronic GVHD (death without extensive chronic GVHD). Univariate analyses were performed using the log-rank test for Kaplan-Meier estimates and Gray's test for competing risk incidences. Continuous variables in univariate analysis were categorised around the median. Factors considered in univariate analysis were: cryopreserved vs fresh PBSC, transplant date, age, sex, diagnosis (myeloid vs lymphoid), disease status (CR vs not in CR), donor (RD vs MUD), donor age, female donor/male recipient pair, patient/donor CMV negative vs either positive, CD34 þ cell dose, conditioning intensity (MAC vs RIC) and in vivo T-cell depletion. Comparison of incidence of primary graft failure requiring CD34
þ selected PBSC 'top-up' was made using Fisher's exact test.
Multivariate analyses of OS and RFS were performed using Cox proportional hazards models, and multivariate analyses of events with a competing risk were performed according to the method of Fine and Gray. 8 Factors differing in distribution between the outcome groups with a P-value of less than 0.1 by univariate analysis, in addition to fresh vs cryopreserved PBSC, were included in an initial multivariate model. Models were refined using a backward approach until only significant associations remained. A P-value of 0.05 was taken as the level of statistical significance. Statistical analyses were performed with R (R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org) and with GraphPad Prism version 5.03 for Windows (Graphpad Software, San Diego, CA, USA).
RESULTS
Patient characteristics and indication for cryopreservation
A total of 76 cryopreserved allo-SCT were identified, including 19 MUD allo-SCT. The control group comprised 123 fresh PBSC allo-SCT, characteristics of the two groups are shown in Table 1 . The cryopreserved group significantly differed from the control group in the following respects: median date of transplant was earlier, patients were older, fewer allo-SCT were from unrelated donors and a greater proportion of transplants comprised female donor/male recipient pairs. Median follow-up of all survivors was 26 months (range 3-77 months). In recipients of MUD allo-SCT, the indication for cryopreservation was always a recipient issue resulting in a need for transplant delay or an alteration in transplant conditioning. This was most commonly intercurrent infection detected at the time of admission for transplant conditioning. Related donor allo-SCT were cryopreserved for one of the following reasons (n): recipient issue resulting in transplant delay (23), donor age (13), donor weight (9), donor comorbidity (6), overseas donor (5) and needlephobia (1).
Engraftment
Cumulative probabilities of neutrophil and platelet engraftment are shown in Figure 1 . The median time to neutrophil engraftment to 40.5 Â 10 9 /L was 12 days for both cryopreserved and fresh PBSC allo-SCT. There was a slight lag in neutrophil engraftment after day 12 in the cryopreserved PBSC recipients, such that probabilities of neutrophil engraftment at day 15 were 92.7% (95% CI 86.2-96.2) vs 73.7% (95% CI 62.1-82.2) for fresh vs cryopreserved PBSC, respectively. By day 30, however, probabilities of neutrophil engraftment were equivalent at 97.6 (95% CI 91.9-99.3) and 98.7% (95% CI 80.6-99.9). Overall, there was a trend toward delayed cumulative neutrophil engraftment in recipients of cryopreserved PBSC (P ¼ 0.067, Figure 1a) . In multivariate analysis cryopreservation, transplant before the median date and CD34 þ dose below median were significantly associated with delayed neutrophil engraftment ( Table 2) . Within the cryopreserved group, neutrophil engraftment did not differ between MUD and RD transplants (median 12 days in both cases, P ¼ 0.51).
Median times to platelet engraftment to 450 Â 10 9 /L were 19 and 14 days for cryopreserved and fresh PBSC, respectively. Platelet engraftment was significantly delayed in recipients of cryopreserved PBSC (Po0.0001). Probabilities of platelet engraftment for cryopreserved vs fresh PBSC were (95% CI): 71.1% (59.3-80) vs 90.2% (83.3-94.4) and 84.2% (73.6-90.8) vs 93.5% (87.1-96.8) at days 30 and 60, respectively (Figure 1b) . In multivariate analysis, receipt of fresh PBSC, transplant after the median date and CD34 þ dose above median were all significantly associated with earlier platelet engraftment ( Table 2) . Within the cryopreserved group, platelet engraftment did not differ between MUD and RD transplants, median day to platelet engraftment was 13 for MUDs and 20 for RD but this difference was not statistically significant (P ¼ 0.14).
For platelet engraftment, the effect of transplant date was investigated further as, given the significant difference in median date of transplant between the cryopreserved and fresh PBSC groups, we wished to ascertain whether all this observed difference was due to the difference between cryopreserved and fresh cells. Considering the fresh PBSC group separately, a Cryopreservation of allogeneic PBSC P Medd et al date of transplant after the median was still significantly associated with earlier platelet engraftment in univariate analysis (P ¼ 0.0077) and there was a trend toward significance in multivariate analysis HR ¼ 1.45, 95% CI 0.954-2.2, P ¼ 0.082). In the smaller cryopreserved group, the association with time did not reach statistical significance.
In all, 11 patients were planned to receive a CD34 þ selected stem cell 'top-up' as treatment for poor engraftment, 9 of the 11 received this (2 died before PBSC could be obtained). In all, 6 of 11 (54.5%) were recipients of cryopreserved PBSC (P ¼ 0.35); of these 6, 5 were RD and 1 was a MUD allo-SCT. The median time to top-up was 121 days (range 15-341). One patient in the fresh PBSC group experienced late secondary graft failure at day 505; there were no late secondary graft failures in the cryopreserved PBSC group.
Survival, relapse and TRM Rates of OS, RFS, relapse and TRM are shown in Table 3 and Figure 2 . There was no significant difference in any of these outcomes between recipients of cryopreserved and fresh PBSC. In multivariate analysis, improved RFS was significantly associated with receipt of a T-replete allo-SCT (HR ¼ 1.65, 95% CI 1.03-2.64, P ¼ 0.038), a lymphoid diagnosis was associated with a significantly reduced relapse incidence (HR ¼ 0.55, 95% CI 0.31-0.99, P ¼ 0.047) and receipt of an unrelated donor transplant was associated with increased TRM (HR ¼ 2.4, 95% CI 1.32-4.38, P ¼ 0.0043).
GVHD
Incidences of acute and chronic GVHD are shown in Table 3 . Neither acute nor chronic GVHD was significantly associated with receipt of cryopreserved PBSC. In multivariate analysis, a CMV negative/negative transplant (HR ¼ 1.64, 95% CI 1.01-2.63, P ¼ 0.045), disease in CR (HR ¼ 1.72, 95% CI 1.01-2.94, P ¼ 0.044) and receipt of MAC allo-SCT (HR ¼ 1.72, 95% CI 1.04-2.86, P ¼ 0.033) were significantly associated with an increased incidence of acute GVHD. For extensive chronic GVHD, a female donor/male recipient pair (HR ¼ 1.71, 95% CI 1.03-2.84, P ¼ 0.038) and MAC (HR ¼ 2.7, 95% CI 1.64-4.55, P ¼ 0.0001) were significantly associated in multivariate analysis.
Impact of donor age and comorbidity As donor age and comorbidity were indications for cryopreservation in the case of related donor allo-SCT, these covariates were considered in analysis of the related donor allo-SCT alone. Recipients of cryopreserved related donor PBSC differed significantly from recipients of fresh related donor PBSC in the following respects: median age (52 vs 44 years, P ¼ 0.0037), median donor age (52 vs 44 years, P ¼ 0.02) and proportion of CMV negative/ negative transplants (35 vs 54%, P ¼ 0.045). The two groups did not significantly differ with regard to other covariates, including the proportion of donors with comorbidities (19.3 vs 9.5%, P ¼ 0.19). In multivariate analysis, including donor age and CI 0.83-0.96, P ¼ 0.0055, respectively). RFS, relapse and TRM rates did not significantly differ between cryopreserved and fresh groups and nor was there any significant association between these outcomes and donor age or comorbidity.
DISCUSSION
This is the first study of long-term follow-up of cryopreserved PBSC allo-SCT to include unrelated donors. In it, we demonstrate that rates of primary engraftment failure, survival, relapse and TRM do not significantly differ between cryopreserved and fresh PBSC when used for allo-SCT. Neutrophil engraftment is significantly delayed following receipt of cryopreserved PBSC; however, we suggest that this delay is of statistical but little clinical significance. The median day of neutrophil engraftment was day 12 for both fresh and cryopreserved groups, and although there was a slight lag in the rate of neutrophil engraftment after the median date, the proportion engrafted by day 30 was identical.
Platelet engraftment is significantly delayed following PBSC cryopreservation. Although PBSC cryopreservation is routine in auto-SCT, the differences inherent in allo-SCT mean that it cannot be assumed that the outcomes of cryopreserved allo-SCT will be equivalent. In particular, allo-SCT carries the risk of immunological rejection of the graft. As cryopreservation might compromise stem cell dose, viability or donor lymphocyte function, 8 the evidence that cryopreservation does not significantly impair engraftment is required before its use can be recommended.
Our finding of delayed platelet engraftment differs from previous studies. 4, 5, 7 In Stockschläder's studies, 4 ,5 the stem cell source was BM and this may account for the difference, as PBSC are associated with earlier platelet engraftment than BM. 10, 11 The median times to platelet engraftment (19 and 14 days to 450 Â 10 9 /L) reported here are earlier than those in Stockschläder's study, where times to platelet count 420 Â 10 9 /L were 22 and 21 days for cryopreserved and fresh BM. 5 PBSC may be more sensitive than BM to the effects of cryopreservation. 8 Kim et al. 7 noted that megakaryocyte colony-forming units suffered significantly greater loss of viability after cryopreservation of PBSC than those of the granulocytic and erythroid lineages, which may explain our observation. Despite this, in clinical data using those cryopreserved PBSC, Kim et al. 7 observed no differences in time to platelet engraftment, although patients receiving cryopreserved PBSC with CFU-Meg in the lowest quartile did demonstrate slower platelet engraftment to 4100 Â 10 9 /L. One study of cryopreserved PBSC in MUD allo-SCT reported a strikingly high incidence of primary engraftment failure. 8 Reassuringly in our study the rate of primary engraftment failure did not significantly differ between cryopreserved and fresh PBSC, and of the six patients who received cryopreserved PBSC and subsequently required a stem cell 'top-up' only one was a MUD transplant.
In this study, higher CD34 þ cell dose and receipt of fresh PBSC were associated with earlier neutrophil engraftment. CD34 þ cell dose is well recognised as being associated with engraftment following allo-SCT as well as after cryopreserved autologous and allogeneic SCT. 7, [12] [13] [14] Earlier platelet engraftment was also significantly associated with fresh PBSC, higher CD34 þ cell dose and transplant after the median date of transplant. The difference was unlikely to be due solely to confounding from the earlier median transplant date of the cryopreserved group, as an effect of date of transplant was also seen in univariate analysis when the fresh PBSC were analysed in isolation, and with a trend toward significance in multivariate analysis. The cause of this effect of transplant date may represent a combination of two factors. First, MAC formed a greater proportion of transplant conditioning before the median date. MAC included MTX as GVHD prophylaxis and this is associated with delayed engraftment. 15 Second, over the period of the study the treatment of early CMV reactivation was changed from ganciclovir to the non-myelosuppressive alternative cidofovir, which may have removed another impediment to marrow reconstitution in some cases.
As RIC continues to expand the use of allo-SCT into older populations, the number of older related donors also increases. In those cases where there are concerns that a PBSC harvest may not yield an adequate cell dose, the data presented here provide reassurance that cryopreservation of the PBSC harvest before commencing conditioning therapy is a viable strategy. In addition, these data have important implications for the management of allo-SCT when inevitable postponements of transplants occur. Lastly, this study is also of relevance to unrelated stem cell donor registries-providing reassurance that cryopreservation of PBSC from MUD is feasible and safe. 
